跳至主要内容
临床试验/NCT04490057
NCT04490057已完成4 期

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

Yale University8 个研究点 分布在 1 个国家目标入组 323 人开始时间: 2020年7月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
323
试验地点
8
主要终点
Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks

研究概览

简要总结

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

详细描述

Using a Sequential Multiple Assignment Randomized Trial (SMART) design, this project is a two-arm, two-stage randomized trial of 320 adult PWH who smoke cigarettes and receive care in one of three health systems (targeted enrollment changed from 632 to 320 with NCI approval and IRB protocol amendment). At inception, participants will be randomized to either combination nicotine replacement therapy (NRT, patch + short-acting NRT) or combination NRT+contingency management (CM). At 12 weeks, responders (non-smoking participants confirmed by exhaled carbon monoxide [eCO] or collateral verification) in both arms will receive 12 more weeks of the same treatment. Non-responders (participants with continued smoking by self-report and/or eCO) in both the NRT and NRT+CM arms will be re-randomized to 12 weeks of treatment, either with medication switch to oral medication, varenicline or bupropion, or intensified level of CM (start CM if no CM during first 12 weeks, or CM with higher reward schedule ["CM plus"] if NRT+CM group initially). The intervention will be delivered by trained clinical pharmacists. The primary outcomes will be self-reported reduction in average cigarettes smoked per day at 24 weeks and 12 weeks (primary outcome changed from eCO-confirmed abstinence to self-reported abstinence with NCI approval and IRB protocol amendment). The specific aims of the proposed study are to: (1) identify the optimal adaptive approach to promote reduced tobacco use (changed from eCO-confirmed smoking abstinence with NCI approval and protocol amendment) (2) study the effectiveness of various adaptive strategies on CD4 count, HIV viral suppression, and VACS index (validated measure of morbidity and mortality risk); and (3) grounded in implementation science and using aHybrid Effectiveness-Implementation Type I design, identify barriers and facilitators to delivering our intervention to inform future implementation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV positive;
  • >= 18 years old
  • Receiving HIV care at Yale-New Haven Hospital, Bridgeport Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic;
  • Have smoked >= 100 cigarettes in lifetime;
  • Currently smokes some days or every day;
  • Smokes, on average, >= 5 cigarettes per day;
  • Able to provide written informed consent.

排除标准

  • Using only non-cigarette nicotine products (i.e., e-cigs, Juul, etc.);
  • Currently using NRT, VAR, or bupropion (defined as use in the prior 7 days);
  • Self-report or urine testing confirming pregnancy, nursing, or trying to conceive;
  • Life-threatening or unstable medical, surgical, or psychiatric condition;
  • Inability to provide at least one collateral contact (family member or friend);
  • Living out of state;
  • Unable to read or understand English (except at Mount Sinai site).

研究组 & 干预措施

12 wks NRT+CM / 12 wks NRT+CM

Experimental

Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.

干预措施: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (Drug)

12 wks NRT+CM / 12 wks NRT+CM

Experimental

Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.

干预措施: Contingency Management (Behavioral)

12 wks NRT+CM/ 12 wks VAR or bupropion+CM

Experimental

Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.

干预措施: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (Drug)

12 wks NRT+CM/ 12 wks VAR or bupropion+CM

Experimental

Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.

干预措施: Varenicline or bupropion (Drug)

12 wks NRT+CM/ 12 wks VAR or bupropion+CM

Experimental

Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.

干预措施: Contingency Management (Behavioral)

12 wks NRT+CM/12 wks NRT+CM plus

Experimental

Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.

干预措施: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (Drug)

12 wks NRT+CM/12 wks NRT+CM plus

Experimental

Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.

干预措施: Contingency Management (Behavioral)

12 wks NRT/ 12 wks NRT

Experimental

Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.

干预措施: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (Drug)

12 wks NRT/ 12 wks VAR or bupropion

Experimental

Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.

干预措施: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (Drug)

12 wks NRT/ 12 wks VAR or bupropion

Experimental

Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.

干预措施: Varenicline or bupropion (Drug)

12 wks NRT/ 12 wks NRT+CM

Experimental

Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.

干预措施: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler (Drug)

12 wks NRT/ 12 wks NRT+CM

Experimental

Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.

干预措施: Contingency Management (Behavioral)

结局指标

主要结局

Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks

时间窗: Week 12

Self reported reduction in average cigarettes smoked per day at 12 weeks

Self Reported Reduction in Average Cigarettes Smoked Per Day at 24 Weeks

时间窗: 24 weeks

Self reported reduction in cigarettes smoked per day at 24 weeks

次要结局

  • Exhaled Carbon Monoxide (eCO) Confirmed Smoking Abstinence at 12 Weeks(12 weeks from baseline)
  • Exhaled Carbon Monoxide (eCO) Confirmed Smoking Abstinence at 24 Weeks(24 weeks from baseline)
  • VACS Index 2.0 Score(24 weeks from baseline)
  • CD4 Count(24 weeks from baseline)
  • HIV Viral Load, Detectable(24 weeks from baseline)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验